Protriptyline HCl Rx
Generic Name and Formulations:
Protriptyline HCl 5mg, 10mg; tabs.
Various generic manufacturers
Indications for Protriptyline HCl:
15–40mg daily in 3–4 divided doses. Increase AM dose if needed; max 60mg daily. Elderly, adolescents: initially 5mg 3 times daily.
During or within 14 days of MAOIs. Concomitant cisapride. Acute post-MI.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults; monitor for clinical worsening or unusual changes. History of seizures. Urinary retention. Increased intraocular tension. Angle-closure glaucoma. Cardiovascular disorders. Bipolar disorder. Mania. Psychosis. ECT. Diabetes. Hyperthyroidism. Liver disorders. Discontinue prior to surgery. Poor metabolizers (CYP2D6). Avoid abrupt cessation. Avoid sun, UV light. Elderly (monitor cardiovascular effects over 20mg/day). Pregnancy. Nursing mothers.
See Contraindications. Hyperpyretic crisis, convulsions, death with MAOIs. Avoid during or within 5 weeks of fluoxetine. Potentiates alcohol, CNS depressants. Blocks guanethidine. Paralytic ileus, hyperpyrexia with anticholinergics, neuroleptics. Potentiated by CYP2D6 inhibitors (eg, quinidine, phenothiazines, SSRIs, propafenone, flecainide); monitor with cimetidine. Adjust sympathomimetic, anticholinergic doses. Increased seizure risk with tramadol.
CNS, anticholinergic, or cardiovascular effects (eg, drowsiness, confusion, anxiety, tachycardia, hypotension), extrapyramidal symptoms, nausea, fatigue, rash, headache, changes in blood sugar, photosensitivity, edema, blood dyscrasias, sexual dysfunction, gynecomastia, liver dysfunction.
Formerly known under the brand name Vivactil.
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- NT-proBNP May Predict Cardiovascular Outcomes in Type 2 Diabetes
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally